Daily Cardiology Research Analysis

This mechanistic study demonstrates that the lncRNA TRDN-AS acts in cis to regulate RNA polymerase II stalling and m6A-dependent transcriptional termination of the cardiac TRDN transcript. Loss of TRDN-AS or METTL3-mediated regulation produces an aberrant triadin isoform, disrupts calcium-release-complex interactions and dyad structure, prolongs the QT interval, and causes dilated cardiomyopathy in mice and humans.

Impact: The paper provides a novel molecular explanation linking RNA processing to excitation-contraction coupling, electrical instability, and cardiomyopathy. Its cross-species validation and identification of a potentially targetable lncRNA–METTL3 pathway substantially advance mechanistic understanding beyond descriptive genetic associations.

Clinical Implications: TRDN-AS-dependent isoform regulation may become a biomarker or therapeutic target for selected cardiomyopathies associated with calcium-handling abnormalities, QT prolongation, or dilated remodeling. Clinical translation will require validation in larger patient cohorts and development of safe methods to modulate lncRNA or m6A-dependent RNA processing.

Future Directions: Future work should define the prevalence of TRDN-AS and TRDN isoform abnormalities across inherited and acquired cardiomyopathies, establish genotype-phenotype relationships, and test targeted RNA-based or epitranscriptomic interventions in long-term in vivo models. Patient-derived cardiomyocytes could support precision-medicine approaches.

BRAVE is an investigator-initiated, multicenter, open-label randomized controlled trial with blinded endpoint adjudication comparing metabolic/bariatric surgery with guideline-based medical weight management in adults with obesity and high-risk cardiovascular disease. Its 200-participant vanguard phase demonstrated feasibility across 17 centers and identified recruitment barriers that were addressed through targeted education and patient engagement.

Impact: This study addresses a major causal evidence gap: whether the cardiovascular benefits suggested by observational bariatric-surgery studies persist in a randomized comparison with contemporary medical therapy. The broad composite endpoint and international multicenter structure could directly inform obesity and cardiovascular disease management if positive.

Clinical Implications: The study establishes a rigorous framework for determining whether bariatric surgery should be incorporated more broadly into cardiovascular risk-reduction strategies for patients with obesity and established cardiovascular disease. Until outcome results are available, surgery should not be assumed to reduce cardiovascular events based solely on this design paper.

Future Directions: The completed BRAVE trial should determine the effect of metabolic/bariatric surgery on each component of the composite outcome, quality of life, renal outcomes, procedural harms, and durability of benefit. Prespecified subgroup analyses should assess effects by heart failure phenotype, diabetes status, atrial fibrillation, and type of surgery.

In a 10-year multicenter retrospective cohort, 13 children with methylmalonic acidemia-associated pulmonary hypertension were compared with 113 children with idiopathic or hereditary pulmonary arterial hypertension. The MMA group had prominent multisystem features and markedly elevated homocysteine; metabolic therapy with hydroxocobalamin, betaine, and related treatments produced complete clinical and hemodynamic remission in all patients within one year, with no relapse during a median 7-year follow-up.

Impact: This study identifies a rare but highly treatable cause of pediatric pulmonary hypertension that can be mistaken for idiopathic disease. Its complete and durable responses support a practical diagnostic change: children with unexplained pulmonary hypertension and multisystem findings should undergo metabolic evaluation, including homocysteine testing.

Clinical Implications: Routine total homocysteine measurement and metabolic screening should be considered in children with unexplained pulmonary hypertension, particularly when growth failure, malnutrition, recurrent pneumonia, hematuria, proteinuria, or other systemic features are present. Correct diagnosis can redirect treatment from chronic pulmonary vasodilator therapy toward metabolite-targeted treatment with potentially curative benefit.

Future Directions: Prospective international studies should validate homocysteine-based screening algorithms, define the optimal metabolic treatment regimen, and determine whether routine screening improves outcomes and reduces misdiagnosis. Molecular and biochemical subclassification may clarify why some patients develop pulmonary vascular disease.